AAD
Author: Willhemenia Loremipsum Special session: Lorem ipsum dolor sit amet Category: Lorem ipsum View all results

Please login or create an account. If you do not have access to this content, you will be shown a 30 second preview and licensing options.

  • Presentation

Morphea Updates

Description

The presentation provides updates on Morphea, a rare sclerosing skin disorder affecting various tissues. It begins with an overview of Morphea, detailing its classifications and typical symptoms, and emphasizes the absence of sclerodactyly and severe Raynaud's phenomenon in patients. Disease pathogenesis involves genetic predisposition followed by environmental factors leading to inflammatory phases characterized by TH-1 and TH-17 responses. Recent research highlights the consistent inflammatory gene signature in active Morphea lesions compared to systemic sclerosis patients. Updated disease measurement tools, including the Low Scat and new imaging techniques, aim to provide better assessments of disease activity. Treatment remains focused on topical steroids for mild cases, while systemic treatments such as methotrexate, mycophenolate, and new therapies like abatacept and tocilizumab are recommended for severe presentations. Recent trials explore new therapeutic methods while emphasizing the importance of addressing quality of life issues for affected patients. The updates underline advancing understanding of Morphea, improved diagnostic tools, and potential new treatments.

View more

Conclusions

  • Morphea is a rare sclerosing disease with various subtypes and distinct pathogenesis characterized by autoimmune features and inflammation.
  • Patients with morphia experience a range of symptoms, including malaise, fatigue, and autoimmune antibodies, without necessarily developing systemic sclerosis.
  • Current research indicates a significant production of interferons and related chemokines such as CXCL9 and CXCL10 during the inflammatory phase of morphia.
  • New pathways for treating morphia are emerging, including the effectiveness of additional therapies such as imatinib, tocilizumab, abatacept, and JAK inhibitors.
  • Disease measurement tools like the Morphea Activity Measure (MAM) and others show promise for assessing treatment efficacy and disease progression.
  • Patients with head and neck morphia require regular ophthalmological examinations due to potential eye involvement.
  • Imaging technologies like 3D stereophotogrammetry and multispectral imaging may enhance our ability to assess morphia activity and treatment outcomes.
  • Monitoring for associated conditions, such as lichen sclerosus and other autoimmune diseases, is vital for comprehensive care of morphia patients.
  • Papara C et al. Morphea: The 2023 update. Front. Med. 2023. 10:1108623.
  • Fett N and Werth VP. Update on morphea. JAAD. 2011;64:217-28.
  • Laxer and Zulian. Localized Scleroderma. 2006. Curr Opin Rheumatol 18:606-613.
  • Leitenberger et al. Distinct autoimmune syndromes in morphea: a review of 245 adult and pediatric cases. Arch Dermatol 2009;145:545-50.
  • Shah J et al. Autoimmune and Cutaneous Inflammatory Comorbidities in Adult-Onset Morphea in the All of Us Research Program. Am J Clin Derm. 2024.
  • Alimova et al. Morphea:baseline body surface involvement and ANA may have a prognostic value. Clin and Exp Dermatology. 2009. 34:e491-92.
  • Arkachaisri et al. Development and initial validation of the localized scleroderma skin damage index and physician global assessment of disease damage: a proof-of-concept study. Rheumatol. 2010. 49(2):373-81.
  • Garcia-Romero MT et al. Development and Validation of the Morphea Activity Measure in Patients With Pediatric Morphea JAMA Derm. 2023;159(3):299-307.
  • Li SC et al. Capturing the Range of Disease Involvement in Localized Scleroderma: The Localized Scleroderma Total Severity Scale. Arthritis and Rheum. 2023. https://doi.org/10.1002/acr.25281.
  • O'Connor C et al. Novel multispectral imaging to predict disease progression in pediatric morphea. Peds Derm. 2024;1-5.
  • Parra-Cares, J. et al. Color Doppler Ultrasound Assessment of Subclinical Activity With Scoring of Morphea. J Cut Med & Surg. 2023. 27(5): 454-460.
  • Zigler CK et al. Cross-sectional quantitative validation of the pediatric Localized Scleroderma Quality of Life Instrument (LoSQI):A disease-specific patient-reported outcome measure. JEADV. 2023. 37:1406-1414.
  • Kreuter A et al. S2k guideline: Diagnosis and therapy of localized scleroderma. JDDG. 2024;1-16.
  • Teske N and N Fett. Recent Advances in Treatment of Systemic Sclerosis and Morphea. Am J Clinical Derm. 2024. 25(2):213-226.
  • Wang C et al. A pilot study on ex vivo expanded autologous adipose-derived stem cells of improving fat retention in localized scleroderma patients. STEM CELLS Trans/ Med.2021. 10:1148-1156.